AMYT7 Jan 2019 07:26
This is sure to get the locals dancing, watch it on opening
AMYT today announces positive results from two pre-clinical studies which support the development of its novel non-viral gene therapy, AP103, as a potentially disease-modifying therapy for patients with Recessive Dystrophic Epidermolysis Bullosa ("RDEB"), a subset of Epidermolysis Bullosa ("EB").